PamGene makes mark with US investors
PamGene, the Dutch biotechnology spin-off of Organon Teknika (a unit ofAkzo Nobel), has managed to raise $6.4 million dollars in its first round of financing. San Francisco, USA-based venture capital firm Alta Partners and European brokers GIMV Venture Capital and Life Sciences Partners were equal investors in the round.
PamGene develops patent-pending technology for a second-generation microarray platform and novel gene expression profiling system for post-genomic applications, an area that is set to grow, according to Jean Deleage, founding partner of Alta. He went on to say that "in today's world of post-genomics, microarray is of high importance," and PamGene should be a major contributor in this field.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze